⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RYTM News
Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
globenewswire.com
RYTM
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
globenewswire.com
RYTM